论文部分内容阅读
目的近几年,大量的长链非编码RNA被发现,通过参与表观遗传、转录和翻译等实现对基因表达的调控,促进肿瘤细胞的发生发展和转移。探究长链非编码RNA RP13-143G15.3在肝癌及癌旁组织中的表达水平,分析其差异表达与临床指标之间的相关性,为肝癌的诊疗提供新的标志物。方法对5例肝癌及癌旁组织进行长链非编码RNA(lncRNAs)表达谱筛查,选择具有表达差异的RP13-143G15.3扩大样本进行验证。收集2016-03-01-2016-06-30广西医科大学肿瘤医院肝胆外科进行肝癌切除术的56例患者肝癌及癌旁组织,采用实时荧光定量PCR技术检测RP13-143G15.3的相对表达水平,并分析其差异表达与患者临床特征、血清学指标及免疫组化指标的相关性。结果5例肝癌组织中RP13-143G15.3表达高于癌旁组织,P=0.005。在大样本56例肝癌组织中相对表达量为0.026 5±0.006,癌旁组织中相对表达量为0.040 7±0.025,肝癌组织中RP13-143G15.3表达明显低于相应癌旁组织(Z=-3.842,P<0.001),与芯片筛查结果不一致。RP13-143G15.3的差异表达与患者乙肝携带史(χ~2=4.667,P=0.031)、门脉高压(χ~2=5.250,P=0.022)、甲胎蛋白水平(χ~2=4.791,P=0.029)、乳酸脱氢酶(Z=-2.237,P=0.025)、谷氨酸脱氢酶(Z=-2.101,P=0.036)、纤维蛋白原(t=-2.103,P=0.040)、CA72-4(Z=-2.147,P=0.032)、免疫学指标CD34(χ~2=9.516,P=0.023)及肿瘤增殖抗原(χ~2=8.000,P=0.005)有关。结论 RP13-143G15.3在肝癌组织中表达下调,其可能起到抑癌作用,有望成为肝癌新的肿瘤标志物及分子靶点,为后续功能研究及机制研究提供理论基础。
In recent years, a large number of long-chain non-coding RNAs have been found to regulate gene expression through epigenetic, transcriptional and translational processes and to promote the development and metastasis of tumor cells. To explore the expression level of long-chain non-coding RNA RP13-143G15.3 in hepatocellular carcinoma and its adjacent tissues, analyze the correlation between the expression of RP13-143G15.3 and clinicopathological parameters, and provide a new marker for the diagnosis and treatment of liver cancer. Methods We screened 5 long-chain non-coding RNA (lncRNAs) expression patterns in hepatocellular carcinoma (HCC) and adjacent normal tissues, and selected the amplified samples with different expression levels for verification. Collected from 2016-03-01-2016-06-30 Cancer Hospital of Guangxi Medical University Hepatobiliary Surgery Fifty-six patients with hepatocellular carcinoma (HCC) and adjacent tissues were enrolled in this study. The relative expression level of RP13-143G15.3 was detected by real-time fluorescence quantitative PCR, And analyze the correlation between the differential expression and clinical features, serological indicators and immunohistochemical indicators. Results The expression of RP13-143G15.3 in 5 cases of HCC was higher than that in paracancerous tissues (P = 0.005). In a large sample of 56 cases of hepatocellular carcinoma, the relative expression was 0.026 5 ± 0.006, while the relative expression in adjacent tissues was 0.040 7 ± 0.025. The expression of RP13-143G15.3 in hepatocellular carcinoma was significantly lower than that in corresponding paracancerous tissues (Z = 3.842, P <0.001), inconsistent with chip screening results. The differences in the expression of RP13-143G15.3 between the two groups were significantly related to the history of hepatitis B (χ ~ 2 = 4.667, P = 0.031), portal hypertension (χ ~ 2 = 5.250, P = 0.022) , P = 0.029), lactate dehydrogenase (Z = -2.237, P = 0.025), glutamate dehydrogenase (Z = -2.101, P = 0.036), fibrinogen ), CA72-4 (Z = -2.147, P = 0.032), immunological markers CD34 (χ ~ 2 = 9.516, P = 0.023) and tumor proliferation antigen (χ ~ 2 = 8.000, P = 0.005) Conclusions The expression of RP13-143G15.3 is down-regulated in hepatocellular carcinoma, which may play a role in tumor suppressor. It is expected to be a new tumor marker and molecular target for hepatocellular carcinoma and provide a theoretical basis for subsequent functional studies and mechanism studies.